Gadsby N J, McHugh M P, Russell C D, Mark H, Conway Morris A, Laurenson I F, Hill A T, Templeton K E
Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Clin Microbiol Infect. 2015 Aug;21(8):788.e1-788.e13. doi: 10.1016/j.cmi.2015.05.004. Epub 2015 May 14.
The frequent lack of a positive and timely microbiological diagnosis in patients with lower respiratory tract infection (LRTI) is an important obstacle to antimicrobial stewardship. Patients are typically prescribed broad-spectrum empirical antibiotics while microbiology results are awaited, but, because these are often slow, negative, or inconclusive, de-escalation to narrow-spectrum agents rarely occurs in clinical practice. The aim of this study was to develop and evaluate two multiplex real-time PCR assays for the sensitive detection and accurate quantification of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. We found that all eight bacterial targets could be reliably quantified from sputum specimens down to a concentration of 100 CFUs/reaction (8333 CFUs/mL). Furthermore, all 249 positive control isolates were correctly detected with our assay, demonstrating effectiveness on both reference strains and local clinical isolates. The specificity was 98% on a panel of nearly 100 negative control isolates. Bacterial load was quantified accurately when three bacterial targets were present in mixtures of varying concentrations, mimicking likely clinical scenarios in LRTI. Concordance with culture was 100% for culture-positive sputum specimens, and 90% for bronchoalveolar lavage fluid specimens, and additional culture-negative bacterial infections were detected and quantified. In conclusion, a quantitative molecular test for eight key bacterial causes of LRTI has the potential to provide a more sensitive decision-making tool, closer to the time-point of patient admission than current standard methods. This should facilitate de-escalation from broad-spectrum to narrow-spectrum antibiotics, substantially improving patient management and supporting efforts to curtail inappropriate antibiotic use.
下呼吸道感染(LRTI)患者常常缺乏积极且及时的微生物学诊断,这是抗菌药物管理的一个重要障碍。在等待微生物学结果期间,患者通常会被给予广谱经验性抗生素,但由于这些结果往往出来得慢、呈阴性或不确定,在临床实践中很少会降级使用窄谱抗菌药物。本研究的目的是开发并评估两种多重实时PCR检测方法,用于灵敏检测和准确定量肺炎链球菌、流感嗜血杆菌、金黄色葡萄球菌、卡他莫拉菌、大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌和鲍曼不动杆菌。我们发现,从痰标本中能够可靠地定量检测出所有8种细菌靶点,最低浓度可达100 CFU/反应(8333 CFU/mL)。此外,我们的检测方法正确检测出了所有249株阳性对照菌株,证明其对参考菌株和本地临床分离株均有效。在一组近100株阴性对照菌株中,特异性为98%。当三种细菌靶点以不同浓度混合存在时,能够准确地对细菌载量进行定量,模拟了LRTI中可能出现的临床情况。对于培养阳性的痰标本,与培养结果的一致性为100%,对于支气管肺泡灌洗液标本为90%,并且检测和定量出了额外的培养阴性细菌感染。总之,一种针对LRTI的8种关键细菌病因的定量分子检测方法有可能提供一种更灵敏的决策工具,比当前标准方法更接近患者入院时间点。这应有助于从广谱抗生素降级使用到窄谱抗生素,大幅改善患者管理并支持减少不适当抗生素使用的努力。